MoonLake Immunotherapeutics' Sonelokimab Shows Promise in Psoriatic Arthritis and HS, Meriting a Buy Rating
TipRanksMay 2 11:45 ET
Strong Buy Rating for MoonLake Immunotherapeutics Based on Promising Sonelokimab Clinical Trials and Market Potential
TipRanksApr 26 14:55 ET
MoonLake Immunotherapeutics: A Promising Outlook With Sonelokimab's Potential in the HS Market
TipRanksApr 23 06:25 ET
Buy Rating Affirmed for MoonLake Immunotherapeutics Amid Promising Clinical Results for Sonelokimab
TipRanksApr 22 12:35 ET
MoonLake Immunotherap Price Target Maintained With a $100.00/Share by HC Wainwright & Co.
MoonLake Immunotherap Price Target Maintained With a $100.00/Share by HC Wainwright & Co.
Dow JonesApr 11 07:37 ET
Express News | HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $100 Price Target
Moomoo 24/7Apr 11 07:27 ET
MoonLake Immunotherapeutics Buy Rating: Strategic Partnerships and Market Potential Fuel Optimism
TipRanksApr 11 06:26 ET
MoonLake Immunotherapeutics, Komodo Health Team Up to Improve Inflammatory Skin, Joint Diseases Treatment
MoonLake Immunotherapeutics (MLTX) and Komodo Health said Wednesday that they signed a three-year partnership to improve treatment of inflammatory skin and joint diseases. The agreement enables the co
MT NewswiresApr 10 14:02 ET
Express News | Moonlake Immunotherapeutics Penned Three-year Technology Partnership With Komodo Health To Advance Research On Inflammatory Skin And Joint Conditions
Moomoo 24/7Apr 10 07:06 ET
MoonLake Immunotherapeutics Inks Three-year Technology Partnership With Komodo Health to Advance Research on Inflammatory Skin and Joint Conditions
MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions MoonLake to tap into Komodo's technology and real-world data to unlock
GlobeNewswireApr 10 07:00 ET
MoonLake Immunotherap Price Target Maintained With a $66.00/Share by Needham
MoonLake Immunotherap Price Target Maintained With a $66.00/Share by Needham
Dow JonesApr 9 06:08 ET
MoonLake Immunotherapeutics: A Strong Buy on Innovation and Strategic Market Positioning
TipRanksApr 9 06:05 ET
Express News | Needham Reiterates Buy on MoonLake, Maintains $66 Price Target
Moomoo 24/7Apr 9 05:57 ET
Goldman Starts MoonLake at Neutral, Cites Lead Drug Potential
Seeking AlphaApr 2 11:21 ET
MoonLake Immunotherap Price Target Announced at $62.00/Share by Goldman Sachs
MoonLake Immunotherap Price Target Announced at $62.00/Share by Goldman Sachs
Dow JonesApr 2 07:16 ET
MoonLake Immunotherap Initiated at Neutral by Goldman Sachs
MoonLake Immunotherap Initiated at Neutral by Goldman Sachs
Dow JonesApr 2 07:16 ET
Express News | Goldman Sachs Initiates Coverage On MoonLake With Neutral Rating, Announces Price Target of $62
Moomoo 24/7Apr 2 07:05 ET
Express News | Watching MoonLake Immunotherapeutics; Shares Spike Higher, Traders Circulate Comments From Betaville
Moomoo 24/7Mar 28 12:02 ET
Trending Stocks Today: Nova Lifestyle Shoots up 54.05% Post-Market
March 21st - US stocks trending post-market.Gainers: $Nova Lifestyle(NVFY.US)$ shoots up 54.05% to $2.85 with a turnover of $6.43 million. $FedEx(FDX.US)$ jumps 12.62% to $298.3 with a turnover of $35
moomoo NewsMar 21 18:00 ET
MoonLake Immunotherapeutics (NASDAQ:MLTX) Is In A Strong Position To Grow Its Business
Yahoo FinanceMar 15 11:36 ET
No Data
No Data